Hide
Show all
Email this article 
Post a Comment A comparative study on the effects of niacin plus atorvastatin with that of fenofibrate plus atorvastatin in dyslipidemia
Abstract
The study was designed to evaluate and compare the effects of co-administration of atorvastatin (10 mg) either with niacin (1 g) or fenofibrate (200 mg) daily for 12 weeks in 67 coronary heart disease patients with dyslipidemia. There were no significant differences among the two groups (35 patients in Group I and 32 patients in Group II) in serum lipid profile except in level of triglyceride reduction where fenofibrate-atorvastatin combination yielded significant (p<0.001) results. SGPT level significantly raised and fasting blood glucose level decreased in fenofibrate-atorvastatin treated group than niacin-atorvastatin combination. Serum creatinine level decreased in niacin-atorvastatin treated group compared to fenofibrate-atorvastatin, but the changes was within normal limit. This study shows that both combinations are equally effective in dyslipidemia. Although, fenofibrate-atorvastatin combination decreased more triglyceride and niacin-atorvastatin combination appeared safer considering some adverse effects.
Keywords: atorvastatin; dyslipidemia; fenofibrate; niacin
Online 19 Apr 2008
DOI: 10.3329/bjp.v3i1.823
Bangladesh J Pharmacol 2008; 3: 8-16.
Keywords
This work is licensed under a Creative Commons Attribution 3.0 License.
IndexCopernicus 2009 value: 9.00; 2010 value: 9.00
SJR h-index 2009 value: 3.00; 2010 value: 4.00
Downloaded by more than 5,000 readers: Saha MR, Alam MA, Akter R, Jahangir R. In vitro free radical scavenging activity of Ixora coccinea L. Bangladesh J Pharmacol. 2008; 3: 90-96.
On average 907 downloads per research article (pdf); 1329 registered user (22 April 2012).
On average 846 downloads per research article (pdf); 1225 registered user (22 December 2011).
On average 814 downloads per research article (pdf); 1117 registered user (22 August 2011).
Abstracted/indexed in (19): Academic Search Complete, Agroforestry Abstracts, Arts & Humanities Citation Index, Asia Journals Online, Bangladesh Journals Online, Biological Abstracts, BIOSIS Previews, CAB Abstracts, Current Abstracts, Directory of Open Access Journals, EMBASE/Excerpta Medica, Forest Products Abstracts, Google Scholar, HINARI (WHO), International Pharmaceutical Abstracts, Open J-gate, Science Citation Index Expanded, SCOPUS and Social Sciences Citation Index.
For longterm preservation, the journal has been archived in the e-Depot archive.
Journal impact analysis 4-years (Harzing's Publish or Perish):
Citation/year: 81.80; Citation/paper: 3.12; h-index: 10.0 (March 20, 2012)
Citation/year: 54.25; Citation/paper: 2.13; h-index: 8.0 (September 8, 2011)
Citation/year: 42.25; Citation/paper: 1.67; h-index: 7.0 (May 29, 2011)
Citation/year: 34.25; Citation/paper: 1.36; h-index: 6.0 (March 13, 2011)
Citation/year: 31.67; Citation/paper: 1.02; h-index: 5.0 (September 2, 2010)
Available in institutional webpage (20): Bangabandhu Sheikh Mujib Medical University; Eastern Michigan University Library;Halmstad University, Sweden; John Hopkins University; National Taiwan University; Oxford University; San Jose State University; Tel Aviv University; Tokyo University of Agriculture; University of Hong Kong; University of Maine; University of Nevada; University of North Carolina; University of Oklahama; University of Saskatchewan; University of Toronto; University of Washington; University of Windsor; Vrije Universiteit Brussel; York University
The Bangladesh Journal of Pharmacology does not accept responsibility for views expressed in articles, mini-reviews, and other contributions that appear in its pages.